NRX Pharmaceuticals (NRXP) Common Equity (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Common Equity of -$13.8 million for Q1 2026, up 45.15% year-over-year from -$9.5 million in Q1 2025, and up 13.41% quarter-over-quarter from -$15.9 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Common Equity (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Common Equity for 10 consecutive years, with -$13.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 45.15% year-over-year to -$13.8 million; the TTM figure through Mar 2026 stood at -$13.8 million (up 45.15% YoY), while the FY2025 annual figure was -$15.9 million, up 31.37% from the prior year.
- Common Equity rose to -$13.8 million in Q1 2026 per NRXP's latest filing, from -$15.9 million in the prior quarter.
- Across five years, Common Equity topped out at $31.7 million in Q1 2022 and bottomed at -$35.6 million in Q2 2025.
- Historically, Common Equity has averaged -$7.7 million across 5 years, with a median of -$13.8 million in 2026.
- Annual changes were most pronounced in 2022 — Common Equity jumped 395.84% — and 2024, when it sank 5205.99%.
- NRX Pharmaceuticals' Common Equity stood at $7.4 million in 2022, then slumped by 258.36% to -$11.7 million in 2023, then slumped by 97.93% to -$23.2 million in 2024, then surged by 31.37% to -$15.9 million in 2025, then climbed by 13.41% to -$13.8 million in 2026.
- Business Quant data shows NRXP's Common Equity at -$13.8 million in Q1 2026, -$15.9 million in Q4 2025, and -$25.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 9.79 Bn |
| 10 | NRX Pharmaceuticals | 130.83 Mn | 104.13 Mn | 426,000.00 | -200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.80 Mn |
| Dec 31, 2025 | -15.94 Mn |
| Sep 30, 2025 | -25.76 Mn |
| Jun 30, 2025 | -35.62 Mn |
| Mar 31, 2025 | -25.16 Mn |
| Dec 31, 2024 | -23.22 Mn |
| Sep 30, 2024 | -18.82 Mn |
| Jun 30, 2024 | -18.39 Mn |
| Mar 31, 2024 | -15.07 Mn |
| Dec 31, 2023 | -11.73 Mn |
| Sep 30, 2023 | -6.22 Mn |
| Jun 30, 2023 | -2.81 Mn |
| Mar 31, 2023 | -284,000.00 |
| Dec 31, 2022 | 7.41 Mn |
| Sep 30, 2022 | 16.78 Mn |
| Jun 30, 2022 | 25.35 Mn |
| Mar 31, 2022 | 31.69 Mn |
| Dec 31, 2021 | 20.81 Mn |
| Sep 30, 2021 | 8.48 Mn |
| Jun 30, 2021 | -39.77 Mn |